Sepracor — 3D Molecular Environments for Drug Storytelling and Education

_____________________________________________________________________________________

Case Study Snapshot:

Sepracor needed to communicate complex molecular science across diverse audiences—investors, HCPs, sales teams, and conference attendees—but static PowerPoint decks weren't landing. I reimagined their drug storytelling as an immersive, visual-first experience, transforming abstract molecular structures into explorable environments where pathways became landscapes and binding mechanisms became clear, choreographed sequences.

The result was a complete launch toolkit: animated films, interactive 3D kiosk experiences, investor-ready renders, and lenticular print takeaways—all built from validated PDB data and cleared through med/legal/reg review. The work delivered measurable impact: 50% increase in booth engagement, 20% reduction in training time, and adoption across all launch materials as standard sales training and keynote content.

_____________________________________________________________________________________

Context:

Sepracor needed to explain and differentiate two small-molecule drugs in a way that worked across launch marketing, investor storytelling, sales training, and conferences. The science mattered—but the existing approach (static PowerPoint) wasn’t landing with mixed audiences.

Problem:

The story was too abstract and too technical. Static slides couldn’t convey what made the molecules distinctive or why mechanism-of-action mattered—so comprehension, recall, and confidence suffered across HCPs, patients, sales teams, investors, and partners.

Approach:

• I rebuilt the narrative as an immersive, visual-first experience—turning molecular science into something audiences could see and remember. The creative strategy combined:

• Molecule-as-landscape (making structure legible and iconic)

• Pathways as environments (contextualizing what’s happening biologically)

• Binding as choreography (showing interaction and mechanism with clarity)

• I designed it to work across channels: booth, kiosk, video, and training—not as a one-off “cool demo,” but as reusable launch infrastructure.

What shipped:

• Static renders for investor decks, training, and print

• Animated films featuring binding-site zoom-ins, mechanism-of-action sequences, and pathway storytelling

• Interactive 3D experiences for conference booths and kiosks

• Lenticular print takeaways that carried the 3D story beyond the booth (memorable “walk-away” artifact)

• A reusable production pipeline so additional molecules could be generated efficiently in the future

• Guardrails and scientific accuracy

• Molecular models sourced from PDB files

• Validated through SME review plus medical/legal/regulatory review

• Built explicitly to stay compliant with FDA constraints (no over-claims, strict accuracy, appropriate framing)

Outcomes:

• Improved comprehension and recall across mixed audiences

• Faster onboarding and training for sales and internal teams

• Became standard sales training material and a keynote opener

• Increased conference engagement via kiosk/booth experiences and durable takeaways

Why it mattered:

This transformed drug education from “science on slides” into an experience that was accurate, compliant, and emotionally legible. It made complex molecular differentiation accessible to non-experts while still credible to experts—improving the effectiveness of launch storytelling across sales, training, investor communication, and events.

• Booth engagement increased by 50%.

• Training time reduction was 20%,

• 100% increase in investor meeting usage.

• Used across all launch materials